Home › Funds › Artia Global Partners LP › PTGX

Artia Global Partners LP position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

Artia Global Partners LP reported holding 22,951 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.8M, representing 0.52% of its reported portfolio and ranking #38 among its reported holdings. Artia Global Partners LP has disclosed PTGX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)22.95K sh
Reported value held$2.81M
Portfolio Weight0.52%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Artia Global Partners LP's PTGX position evolved

Artia Global Partners LP first disclosed a stake in PTGX in Q3 2023 at 112,340 shares (US$1.9M). The position peaked in Q1 2025 at 333,851 shares, worth US$16.1M. Across 12 filings, Artia Global Partners LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 22,951 shares valued at US$2.8M. Notable position changes include a 136% increase in Q4 2024 (shares rose 25% over the following quarter), a 93% trim in Q2 2025 (shares rose 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 112.34K $1.87M New
Q4 2023 112.34K $2.58M Hold
Q1 2024 124.44K $3.60M Add
Q2 2024 124.44K $4.31M Hold
Q3 2024 124.44K $5.60M Hold
Q4 2024 293.85K $11.34M Add
Q1 2025 333.85K $16.15M Add
Q2 2025 22.95K $1.27M Reduce
Q3 2025 22.95K $1.52M Hold
Q4 2025 22.95K $2.00M Hold
Q1 2026 22.93K $2.42M Hold
Q2 2026 22.95K $2.81M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has Artia Global Partners LP held PTGX?

Artia Global Partners LP has disclosed PTGX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Artia Global Partners LP's current position in PTGX?

As of Q2 2026, Artia Global Partners LP holds 22.95K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $2.81M, representing 0.52% of its reported portfolio and ranking #38.

Has Artia Global Partners LP been buying or selling PTGX?

In the latest 13F filing (Q2 2026), Artia Global Partners LP held unchanged its position in PTGX. The position peaked in Q1 2025 at 333.85K shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.